Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Dec 6;13(12):e20203.
doi: 10.7759/cureus.20203. eCollection 2021 Dec.

Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature

Affiliations
Case Reports

Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature

Mathew Chatham et al. Cureus. .

Abstract

Anti-Yo-associated paraneoplastic cerebellar degeneration (PCD) syndrome is a very rare condition that is most commonly associated with breast and gynecologic cancers. Those cases associated with breast cancer tend to be human epidermal growth factor receptor 2 (HER2)-positive, though the reason for this correlation is unknown. Most commonly, the neurologic symptoms of the PCD syndrome predate the patient's cancer diagnosis. Thus, prompt diagnosis of PCD is essential to allow for early treatment of the neurologic symptoms and the underlying malignancy. However, the prognosis is very poor for the anti-Yo-associated paraneoplastic syndrome, since neurologic damage is usually rapid and irreversible. Further progression may be stopped with appropriate treatment of cancer, but existing neurologic deficits at the time of diagnosis are usually permanent. Steroids, plasma exchange, and rituximab are commonly used treatments, though these have had mixed to poor results.

Keywords: anti-yo antibody; breast cancer; gynecologic cancer; paraneoplastic cerebellar degeneration; paraneoplastic neurologic syndrome; paraneoplastic syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Positron emission tomography (PET) scan from case 3 showing para-aortic lymphadenopathy, with standard uptake value (SUV) 18.5

Similar articles

Cited by

References

    1. Paraneoplastic syndromes: an approach to diagnosis and treatment. Pelosof LC, Gerber DE. Mayo Clin Proc. 2010;85:838–854. - PMC - PubMed
    1. Paraneoplastic neurological syndromes. Honnorat J, Antoine JC. Orphanet J Rare Dis. 2007;2 - PMC - PubMed
    1. Managing paraneoplastic neurological disorders. De Beukelaar JW, Sillevis Smitt PA. Oncologist. 2006;11:292–305. - PubMed
    1. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Venkatraman A, Opal P. Ann Clin Transl Neurol. 2016;3:655–663. - PMC - PubMed
    1. Plasma exchange for treating anti-Yo-associated paraneoplastic cerebellar degeneration: case report and literature review. Hu FQ, Shang FR, Liu JJ, Yuan H. Medicine (Baltimore) 2020;99 - PMC - PubMed

Publication types

LinkOut - more resources